ReviewNeurogenetics2026
Expanding mutational and phenotypic spectrum of CST3-related leukoencephalopathy: a novel family and literature review.
Review in Neurogenetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
CST3-related leukoencephalopathy is a recently recognized adult-onset neurodegenerative disorder caused by pathogenic CST3 variants with C-terminal truncations, frameshifts, or deletions. Owing to the limited number of reported cases, its clinical and radiological spectrum remains incompletely defined. Here, we report a Chinese family harboring a novel heterozygous nonsense variant of CST3 (c.327C > A; p.Cys109*), which represents the most 5’ pathogenic mutation identified to date. The proband, a 62-year-old woman, presented with recurrent encephalopathic episodes, progressive cognitive decline, tremor, urinary retention, and reduced serum cystatin C levels. Longitudinal MRI revealed extensive white matter lesions with persistent diffusion-weighted imaging (DWI) hyperintensities along the corticomedullary junction and the corpus callosum, which used to be viewed as a diagnostic marker of neuronal intranuclear inclusion disease. However, the possibility of neuronal intranuclear inclusion disease was excluded through comprehensive genetic and pathological evaluations. Notably, an asymptomatic young carrier already demonstrated white matter abnormalities with DWI hyperintensities, indicating that radiological changes can substantially precede clinical onset. Our findings expand the mutational and phenotypic spectrum of CST3-related leukoencephalopathy and highlight overlapping clinical and radiological features among adult-onset leukoencephalopathies presenting with corticomedullary junction DWI hyperintensities and episodic manifestations.
Indexed as
Identifiers
41870654What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.